THE diagnosis of pericardial effusion and pericarditis is often difficult. The history and physical signs can be misleading, and the electrocardiogram is frequently equivocal. A high index of ...
MAVERIC-2 is expected to initiate in Q4 2024 at major pericardial disease centers across the United States and Europe, with results anticipated ahead of the company’s planned pivotal Phase III MAVERIC ...
Receive the the latest news, research, and presentations from major meetings right to your inbox. TCTMD ® is produced by the Cardiovascular Research Foundation ® (CRF). CRF ® is committed to igniting ...